A client is receiving benztropine mesylate for drug-induced extrapyramidal syndrome (EPS). Which finding indicates that the nurse should further evaluate the client?

Choice A reason: Decreased bowel movements (constipation) are a common side effect of benztropine due to its anticholinergic properties, but they do not indicate worsening EPS or treatment failure. Increased mouth movements suggest persistent or worsening EPS, requiring further evaluation, making constipation less critical for immediate reassessment.Choice B reason: Decreasing hand tremors indicate benztropine’s effectiveness in treating EPS, as it reduces parkinsonian symptoms like tremors. This is a desired outcome, not a cause for further evaluation. Increased mouth movements, suggesting tardive dyskinesia or EPS persistence, are more concerning, making this incorrect.Choice C reason: Increased mouth movements, such as tardive dyskinesia or dystonia, suggest worsening or inadequately controlled EPS, potentially indicating benztropine’s ineffectiveness or a need for dose adjustment. This finding warrants further evaluation, aligning with psychopharmacology evidence for monitoring anticholinergic therapy, making it the correct choice.Choice D reason: Dry mouth is a common anticholinergic side effect of benztropine, not an indicator of EPS worsening. It is expected and manageable, unlike increased mouth movements, which signal potential EPS complications. This finding does not require immediate evaluation, making it incorrect for further nursing assessment.